Virtual Grand Rounds: Pharmacological Management of Adolescent Depression: Evidence-Based and Emerging Treatments

Dr. Michael Bloch discusses the significant public health burden associated with pediatric depression and related conditions. First-line treatments for pediatric depression as well as their current evidence base will then be discussed. Treatment-resistant depression will be defined in adolescents and then we will discuss the evidence behind commonly used pharmacological strategies for adolescents with TRD and their current evidence base. We will lastly discuss data on emerging treatments for adolescent depression including ketamine, ECT, and rTMS.

As a result of participating in this activity, learners should be able to:

Describe the substantial health burden associated with pediatric depression and suicidality
Name current evidence-based treatments for pediatric depression
Describe the current evidence base for pharmacological and interventional treatment strategies for treatment-resistant depression in youths